At the same time paracrine IL-6 can limit NF-κB-dependent anti-viral and anti-tumor immune responses in APCs, further highlighting IL-6 as an attractive target for adjuvant immunotherapy of cervical cancer. This evidence concerns the gene NFKB1 and cervical cancer.